サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：輸血診断の世界市場-2022-2029
市場調査レポート
商品コード
1153814

輸血診断の世界市場-2022-2029

Global Transfusion Diagnostics Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
輸血診断の世界市場-2022-2029
出版日: 2022年11月15日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場の概要

輸血診断市場は、2021年に39億5529万米ドルとなり、2029年には67億735万米ドルに達し、予測期間（2022年～2029年）にCAGR9.68%で成長すると予測されています。

輸血とは、血液を体内に送り込むことです。輸血は、失われた血液成分を補うために、さまざまな病状で使用されます。輸血は、手術中や重傷により失われた血液を補うものです。また、血液がんなどの病気により、体内で血液がうまく作れない場合にも輸血が行われることがあります。

市場力学

血液がん、重傷者、事故などの発生率の増加により、これらの診断薬の需要が増加しています。手術件数の増加、研究開発費の増加、新規製品の上市の増加が市場成長の原動力になると予想されます。

新規製品の発売の増加、重傷者や事故事例の増加などが市場成長の原動力となります。

輸血診断の世界市場は、血液がん、貧血、鎌状赤血球貧血、腎臓病、輸血感染症などの重篤な感染症などの慢性疾患の増加による医療業界の診断薬需要に主に牽引されています。事故や外傷、痛みを伴う手術の増加により、市場の成長が促進されます。例えば、2022年8月、QuidelOrtho Corporationは、子会社の体外診断サービスプロバイダーのOrtho Clinicalが開発したOrthoワークステーションについて、AABB「標準準拠」指定品質シールを取得したと発表しました。このワークステーションは、インキュベーターと遠心分離機が一体となった2in1機能を持つ血液検査システムです。

様々な資金調達、斬新な技術の進歩、最新の革新的な製品の発売数が増加しており、これらの輸血診断の高い需要につながっています。例えば、2022年7月、ロシュは、単一のヒトサンプルによってC型肝炎ウイルス抗体と抗原の状態を独立して検出できる初のイムノアッセイ、Elecsys HCV Duoイムノアッセイを発売しました。この検査は、感染の早期発見が可能であり、患者の回復期や慢性的な感染症状を示す場合に使用することができます。

輸血診断に関連する高コストは、市場の成長を阻害します。

しかし、輸血診断の品質が保証されたキットや器具が高いことが、成長を抑制する主な要因となっています。経験豊富な専門家がいないため、自動化された機器を扱い、正確な結果を出すことが困難です。

COVID-19影響分析

パンデミックは、世界の財政的な期待、オペレーション、危機対応戦略にマイナスの影響を及ぼしています。COVID-19の発生は、ヘルスケア産業に深刻な影響を及ぼしています。輸血診断市場は、すべての献血が中止されたため、COVIDによる莫大な損失を経験しました。COVIDや輸血感染症が蔓延したため、人々は輸血を受けることを拒否したのです。しかし今、市場参入企業は、研究市場を活用し、パンデミックに対抗するための最先端のアイテムを生み出すことで、長期的・短期的な成長戦略を変えようとしています。世界中で様々な取り組みやコラボレーション、合併が行われ、市場の成長を後押ししています。例えば、2022年8月、体外診断革新技術プロバイダーのQuidelOrtho Corpは、血液供給強化のために血液・生物療法振興協会が設立した連合、アライアンスへの参加を発表しました。

目次

第1章 市場調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 新製品上市の増加
      • 輸血用診断薬の需要増加
    • 抑制要因
      • 輸血用診断機器に関連する高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターの5つの力
  • アンメットニーズ
  • サプライチェーン分析
  • 規制分析

第6章 COVID-19分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 製品タイプ別

  • 機器・キット
  • 試薬
  • その他

第8章 輸血タイプ別

  • 赤血球輸血
  • 血小板輸血
  • 血漿輸血
  • 全血輸血

第9章 アプリケーション別

  • 疾患スクリーニング
  • 血液型検査
  • その他

第10章 エンドユーザー別

  • 血液銀行
  • 病院
  • ラボラトリー
  • 血漿分画施設
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第13章 企業プロファイル

  • Ortho Clinical Diagnostics
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Beckman Coulter
  • Quotient Limited
  • Abbott Laboratories
  • Diagast
  • Becton, Dickinson & Company
  • Immucor Inc.
  • Grifols S.A.
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche Ltd.

第14章 輸血診断薬の世界市場-DataM

目次
Product Code: DMMDP858

Market Overview

Transfusion Diagnostics Market was valued at US$ 3,955.29 million in 2021 and is estimated to reach US$ 6,707.35 million by 2029, growing at a CAGR of 9.68% during the forecast period (2022-2029).

Blood transfusion is the process of transferring blood to the body. Transfusions are used for various medical conditions to replace lost blood components. Blood transfusions replace blood lost during surgery or due to a severe injury. A transfusion also may be done if the body can't make blood properly because of an illness such as blood cancer.

Market Dynamics

The increasing demand for these diagnostic products is due to the rising incidence of blood cancer, serious injuries, and accidents. The rising number of surgeries, increasing research and development expenditure and growth in novel product launches are expected to drive market growth.

The increasing novel product launches and rising number of serious injuries and accident cases will drive market growth.

The global market for transfusion diagnostics is primarily driven by the healthcare industry's demand for diagnostic products due to increasing chronic illnesses, including blood cancer, anemia, sickle cell anemia, kidney disease and serious infection such as transfusion-transmitted infections. The rising number of accidents, trauma and painful surgeries drive the market's growth. For instance, in Aug 2022, QuidelOrtho Corporation announced receiving AABB "standards compliant" designation quality seal for an Ortho workstation developed by its subsidiary, Ortho Clinical, in vitro diagnostic services provider. This workstation is a blood testing system that has a 2-in-1 feature as it combines an incubator and a centrifuge.

Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these transfusion diagnostics. For instance, in July 2022, Roche launched Elecsys HCV Duo immunoassay, the first immunoassay that permits independent detection of hepatitis C virus antibodies and antigen status by a single human sample. This test can detect the infection at an early stage and can be used during the patient's recovery phase or when showing chronic infection symptoms.

The high costs associated with transfusion diagnostics will hamper the market's growth.

However, high rates of quality-assured kits and instruments for transfusion diagnostics are the major factor restraining the growth. The unavailability of experienced professionals makes it difficult to handle the automated instruments and provide accurate results.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The transfusion diagnostics market has experienced huge losses due to COVID, as all the blood drives were canceled. People refused to get transfusions because of the spread of COVID and transfusion-transmitted infections. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Aug 2022, QuidelOrtho Corp, in vitro diagnostic innovative technology provider, announced joining the Alliance, a coalition established by the Association for Advancement of Blood and Biotherapies to strengthen the blood supply.

Segment Analysis

The disease screening segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The disease screening segment is the highest market holder in the global transfusion diagnostics market. All the blood donated is screened to get evidence of the absence of any infection in the blood before releasing the blood and its components for clinical use, which is known as disease screening. Introducing serological assays that target virus-specific antigens and antibodies is very useful for detecting infection in donated blood, such as transfusion-transmitted infectious agents like TTIs, HIV, hepatitis B virus and hepatitis C virus. The latest nucleic acid amplification technology screening effectively minimizes the risk of infection.

Disease screening dominates the market due to increased blood cancer cases globally. According to the World Health Organization, in 2022, approximately 1.24 million blood cancer cases occur globally annually. The rising number of people suffering from blood-related disorders, regulatory approvals and growing technological advancements or research/clinical trial studies drive the market's growth. For Instance, in Jun 2022, Grifols, plasma-derived therapy and innovative diagnostic solutions developer, announced receiving the CE mark for Procleix Plasmodium Assay, 1st automatic nucleic acid test system specially designed for blood donors for patients related to malaria.

Geographical Analysis

North America region holds the largest market share of the global transfusion diagnostics market.

North America dominates the global transfusion diagnostics market, primarily attributed to the rising prevalence of chronic ailments such as blood cancer, anemia, hemophilia, kidney disease and many more due to changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to North America's rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the World Health Organization, in 2022, more than 2 million people will suffer from anemia globally, affecting around 25% of the world's population.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Sep 2022, Grifols, a plasma medicine manufacturer, announced its agreement with Canada's national blood authority, Canadian Blood Services, to expand its self-sufficiency in essential plasma protein therapies and immunoglobulin medicines.

Competitive Landscape

The transfusion diagnostics market is highly competitive with local and global companies' presence. Ortho Clinical Diagnostics, Beckman Coulter, Quotient Limited, Abbott Laboratories, Diagast, Becton, Dickinson & Company, Immucor Inc., Grifols S.A., Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in May 2022, Quidel Corporation announced transaction completion to combine with Ortho Clinical Diagnostics Holdings to form QuidelOrtho Corporation, in vitro diagnostic products and services provider company.

Ortho Clinical Diagnostics:

Overview:

Ortho Clinical Diagnostics is a company that provides in vitro diagnostic equipment for blood typing. It produces automated and semiautomated testing products and testing menu products. It was established in 1939 and is headquartered in New Jersey, United States.

Product Portfolio:

Ortho Vision Platform: This platform comprises analyzers that test the compatibility of blood to make sure that patients receive the correct blood type during transfusion. Ortho vision products are designed for high-volume labs, allowing complex immunohematology testing, including serial dilutions, identifying particular cell antibodies and reflex tests.

Key Development: In Sep 2021, Ortho Clinical Diagnostics, an in vitro diagnostic company, announced the launch of Immediate Spin Crossmatch (ISXM) that will provide aid in determining the incompatibility during blood transfusion between the recipients and donors. This serological test determines the incompatibility of ABO blood type between the recipient plasma and donor RBCs.

The global transfusion diagnostics market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising novel product launches
      • 4.1.1.2. Increasing demand for diagnostic transfusion products
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost associated with diagnostic transfusion instruments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply chain Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Instruments & Kits*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Reagents
  • 7.4. Others

8. By Transfusion Types

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 8.1.2. Market Attractiveness Index, By Transfusion Types
  • 8.2. Red Blood Cell Transfusion *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Platelet Transfusion
  • 8.4. Plasma Transfusion
  • 8.5. Whole Blood Transfusion

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Disease Screening *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Blood Typing
  • 9.4. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Blood Banks*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Hospitals
  • 10.4. Laboratories
  • 10.5. Plasma Fractionation Facilities
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Ortho Clinical Diagnostics
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Beckman Coulter
  • 13.3. Quotient Limited
  • 13.4. Abbott Laboratories
  • 13.5. Diagast
  • 13.6. Becton, Dickinson & Company
  • 13.7. Immucor Inc.
  • 13.8. Grifols S.A.
  • 13.9. Bio-Rad Laboratories
  • 13.10. F. Hoffmann-La Roche Ltd.

LIST NOT EXHAUSTIVE

14. Global Transfusion Diagnostics Market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us